Press Release: HALIX and Leiden University sign agreement

New facilities for HALIX at the Leiden Bio Science Park
Leiden (the Netherlands), 21.12.2017 – HALIX B.V. and the Leiden University signed an agreement for a plot of land at the Leiden Bio Science Park. This represents the kick-off for the final designing phase and start of the constructing phase of HALIX’s brand-new GMP facilities.
HALIX is expanding the scope of its services, requiring additional capacity which will be created in a new, approx. 6.500 m2 facility located centrally in the Leiden Bio Science Park, the Netherlands. These new facilities will be designed for state of the art GMP manufacturing projects.
“Signing the agreement with the Leiden University makes it possible to start building our new GMP facilities. It enables us to further support our customers’ needs.” says Alex Huybens, Managing Director of HALIX. “This ensures future growth capacity of our company. The Leiden Bio Science Park is the perfect environment for our activities, so we are happy with the location offered by the Leiden University.”
The Leiden Bio Science Park is the largest science cluster in the Netherlands and brings together Leiden University, Leiden University Medical Center (LUMC), and approximately 150 companies in close proximity. There is a lot of energy and expertise moving around between companies in the Bio Science Park. Being part of that is a great benefit for HALIX.

HALIX is a contract manufacturing organization (CMO) based in Leiden, the Netherlands, licensed for clinical and commercial GMP contract manufacturing of biopharmaceuticals. We provide services to biopharmaceutical partners, enabling them to harvest on their research activities and to enter and supply their markets with the most efficient use of resources. Our focus is GMP manufacturing of biologics, by manufacturing drug substance through mammalian cell culturing, and by performing aseptic fill and finish and lyophilization services. Within the next years we are extending the scope of services for therapeutic proteins and viral vaccines. More information is available on:
HALIX was founded in 2012 as a 100% subsidiary HAL Allergy Holding B.V., internationally known as HAL Allergy Group, The HAL Allergy Group belongs to the family owned Droege Group AG. More information is available on